Westend Brokers AG
Silvia Quandt & Cie. AG, Brokerage & Investment Banking: In-between the lines – Bernhard Eschweiler
Silvia Quandt & Cie. AG, Merchant & Investment Banking / Schlagwort(e): Sonstiges – This was not the last time Karlsruhe had to rule on Euro-area legislation – Full sterilization of OMTs has no impact if ECB provides banks unlimited liquidity – Growing market optimism is mostly but not only policy driven The German High Court rejected the complaints against the ESM yesterday as ‘fundamentally unfounded‘. In summary, the court stated that the degree of Germany’s fiscal involvement in response to the Euro crisis is a political and not a legal decision as long as par-liament is in control and contractual liability limits are binding. The court further stated that the conditionality is implicitly met and only urged the government to make it more explicit. The ESM has now the green light. How soon it will get started, however, remains unclear. Clear is that this was not the last time the German High Court had to rule on Euro-area legislation. The crisis is by far not over, more coordinated action and legislation is likely to follow and the road to Karlsruhe is easy. ECB is ready but may not act soon The market reaction to the Karlsruhe ruling was positive but not euphoric as a favorable outcome was widely expected. Much more euphoric was the market reaction to last week’s ECB announcement. The ECB surprised markets positively in three ways: – First, the fact that the ECB outlined the modalities of its new bond purchase program (OMT) at all. We as well as much of the market had expected a delay until after September 12. – Second, the statement that OMTs will be ex ante unlimited in size. Previously, ECB president Draghi talked about adequate size. – Third, the announcement that the maturity range will be up to three years. Earlier, ECB president Draghi described the new bond purchases as a form of money market operations, which would imply a maximum maturity of one year. A potentially negative (but not much noticed) surprise for markets was the statement that OMTs will be fully sterilized. Earlier statements by ECB president Draghi suggested that the operations would not or only partially be sterilized. Full sterilization is probably a concession to those ECB council members who worry more about inflationary implications. The question is whether unlimited bond purchases can have the desired effect if they are fully sterilized. The answer depends on the type of sterilization and the overall monetary policy stance. Strictly speaking, sterilization means that one operation is offset by an opposite operation on the same side of the balance sheet so that the overall size of the balance sheet remains unchanged. An example would be if the ECB reduces the lending to banks by the same amount as the bond purchases. Balance-sheet-neutral sterilization is sometimes used for FX interventions, but undermines their effectiveness. Anyway, this is not what the ECB has done to sterilize the SMP operations in the past. The ECB has chosen a softer form of sterilization. It has absorbed the extra liquidity created by the bond purchases on banks’ ECB current account by auctioning one-week term deposits (see box on previous page). In that case, the balance sheet expands but banks cannot immediately spend the extra money. Success of that operation depends on the interest rate that the ECB offers to banks. Despite a few failed auctions, this sterilization has technically worked (see table on previous page) and is probably what the ECB will do with the OMTs as well. In practice, the sterilization effect depends critically on the overall monetary policy stance. In the first year of the SMP, the ECB has tried to normalize its policy (interest rates). The balance sheet shrunk by nearly 5% as increases in gold and FX reserves as well as domestic securities were more than offset by a 45% reduction in lending to banks (see table on previous page). After June 2011, ECB policy has been reversed. In response to the collapse of the interbank market between the periphery and the core the ECB has provided unlimited liquidity with longer maturities and softer collateral standards and cut interest rates. Since then, the ECB balance sheet has expanded 63% as lending to banks has surged 185%. Without that policy shift, the Euro would most likely have collapsed. As long as the ECB maintains this accommo-dative stance, which is what we expect, full sterilization will not hamper the effectiveness of OMTs. The ECB may be hoping that the announcement of ex ante unlimited bond purchases will be enough to stabilize markets and that it never actually needs to activate OMT. Indeed, the honeymoon may last a while, but sooner or later stress is set to reemerge. Greece, for example, may trigger the next round of market volatility and cause renewed trouble for Spain. Would Spain then request and get EFSF/ESM support? In our judgment, Spain will eventually request help just as it did in June, but only in form of a precautionary credit line. First, the Spanish government will do anything to avoid large additional reforms. Second, German support for a full package is very unlikely, given its potential size and what that means for the resources of EFSF and ESM. Spain is widely viewed as compliant and approval of a precautionary credit line is likely. Nevertheless, a fierce debate in Germany is pre-programmed as approval automatically implies giving the ECB the green light for potentially unlimited bond purchases. Once a Spanish program is approved, which may take a while, we expect the ECB to act fast and squeeze the market. That is the only way the ECB can hope to restore orderly market conditions without having to be permanent in the market. Market sentiment beats business confidence The ECB has contributed significantly to the turn in market sentiment, but it is not the only driver. Markets turned first after the Spanish bank recapitalization program in June and the subsequent EU summit. Moreover, good news came not only from the Euro area. In the US, there is a growing sense that the fiscal cliff will look more like a speed bump and the Fed seems ready to launch another round of quantitative easing. China is also easing both fiscal and monetary policy and there are more signs of policy easing across both developed and emerging markets. Yet the growing market optimism is not having much impact on business sentiment so far. Indeed, most output and labor market indicators support the growing business pessimism and highlight the risks ahead. Nevertheless, the global economy is in our judgment at a turning point. First, global demand dynamics, especially consumption, is improving. Global car sales, for example, are up about 17% from last year with no visible fading of momentum in recent months. Second, the growing impatience of policymakers with the poor growth performance is triggering ever more aggressive policy responses and in aggregate may well lead to an overreaction. To be sure, market sentiment is fickle and can flip quickly and risks that the economic slowdown gains more momentum are plenty. Yet, we believe that chances are larger that policy action and the private-sector response will produce stronger growth, especially going into 2013. Disclaimer This analysis was prepared by Bernhard Eschweiler, Senior Economic Advisor, and was first published 14 September 2012, Silvia Quandt Research GmbH, Grüneburgweg 18, 60322 Frankfurt is responsible for its preparation. German Regulatory Authority: Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Str. 108, 53117 Bonn and Lurgiallee 12, 60439 Frankfurt. Publication according to article 5 (4) no. 3 of the German Regulation concerning the analysis of financial instruments (Finanzanalyseverordnung):
Company disclosures Article 34b of the German Securities Trading Act (Wertpapierhandelsgesetz) in combination with the German regulation concerning the analysis of financial instruments (Finanzanalyseverordnung) requires an enterprise preparing a securities analysis to point out possible conflicts of interest with respect to the company or companies that are the subject of the analysis. A conflict of interest is presumed to exist, in particular, if an enterprise preparing a security analysis: (a) holds more than 5 % of the share capital of the company or companies analysed; (b) has lead managed or co-lead managed a public offering of the securities of the company or companies in the previous 12 months; (c) has provided investment banking services for the company or companies analysed during the last 12 months for which a compensation has been or will be paid; (d) is serving as a liquidity provider for the company’s securities by issuing buy and sell orders; (e) is party to an agreement with the company or companies that is the subject of the analysis relating to the production of the recommendation; (f) or the analyst covering the issue has other significant financial interests with respect to the company or companies that are the subject of this analysis, for example holding a seat on the company’s boards. In this respective analysis the following of the above-mentioned conflicts of interests exist: none Silvia Quandt Research GmbH, Silvia Quandt & Cie. AG, and its affiliated companies regularly hold shares of the analysed company or companies in their trading portfolios. The views expressed in this analysis reflect the personal views of the analyst about the subject securities or issuers. No part of the analyst’s compensation was, is or will be directly or indirectly tied to the specific recommendations or views expressed in this analysis. It has not been determined in advance whether and at what intervals this report will be updated. Equity Recommendation Definitions Silvia Quandt Research GmbH analysts rate the shares of the companies they cover on an absolute basis using a 6 – 12-month target price. ‘Buys’ assume an upside of more than 10% from the current price during the following 6 – 12-months. These securities are expected to out-perform their respective sector indices. Securities with an expected negative absolute performance of more than 10% and an under-performance to their respective sector index are rated ‘avoids’. Securities where the current share price is within a 10% range of the sector performance are rated ‘neutral’. Securities prices used in this report are closing prices of the day before publication unless a different date is stated. With regard to unlisted securities median market prices are used based on various important broker sources (OTC-Market). Disclaimer This publication has been prepared and published by Silvia Quandt Research GmbH, a subsidiary of Silvia Quandt & Cie. AG. This publication is intended solely for distribution to professional and business customers of Silvia Quandt & Cie. AG. It is not intended to be distributed to private investors or private customers. Any information in this report is based on data obtained from publicly available information and sources considered to be reliable, but no representations or guarantees are made by Silvia Quandt Research GmbH with regard to the accuracy or completeness of the data or information contained in this report. The opinions and estimates contained herein constitute our best judgement at this date and time, and are subject to change without notice. Prior to this publication, the analysis has not been communicated to the analysed companies and changed subsequently. This report is for information purposes only; it is not intended to be and should not be construed as a recommendation, offer or solicitation to acquire, or dispose of, any of the securities mentioned in this report. In compliance with statutory and regulatory provisions, Silvia Quandt & Cie. AG and Silvia Quandt Research GmbH have set up effective organisational and administrative arrangements to prevent and avoid possible conflicts of interests in preparing and transmitting analyses. These include, in particular, inhouse information barriers (Chinese walls). These information barriers apply to any information which is not publicly available and to which any of Silvia Quandt & Cie. AG and Silvia Quandt Research GmbH or its affiliates may have access from a business relationship with the issuer. For statutory or contractual reasons, this information may not be used in an analysis of the securities and is therefore not included in this report. Silvia Quandt & Cie. AG and Silvia Quandt Research GmbH, its affiliates and/or clients may conduct or may have conducted transactions for their own account or for the account of other parties with respect to the securities mentioned in this report or related investments before the recipient has received this report. Silvia Quandt & Cie. AG and Silvia Quandt Research GmbH or its affiliates, its executives, managers and employees may hold shares or positions, possibly even short sale positions, in securities mentioned in this report or in related investments. Silvia Quandt & Cie. AG in particular may provide banking or other advisory services to interested parties. Neither Silvia Quandt Research GmbH, Silvia Quandt & Cie. AG or its affiliates nor any of its officers, shareholders or employees accept any liability for any direct or consequential loss arising from any use of this publication or its contents. Copyright and database rights protection exists in this publication and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of Silvia Quandt Research GmbH. All rights reserved. Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. The value of, or income from, any investments referred to herein may fluctuate and/or be affected by changes in exchange rates. Past performance is not indicative of future results. Investors should make their own investment decisions without relying on this publication. Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuer or market discussed herein and other persons should not take any action on the basis of this publication. Specific notices of possible conflicts of interest with respect to issuers or securities forming the subject of this report according to US or English law: None This publication is issued in the United Kingdom only to persons described in Articles 19, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 and is not intended to be distributed, directly or indirectly, to any other class of persons (including private investors). Neither this publication nor any copy of it may be taken or transmitted into the United States of America or distributed, directly or indirectly, in the United States of America. Frankfurt am Main, 14.09.2012
Ende der Corporate News 14.09.2012 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch die DGAP – ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. Medienarchiv unter http://www.dgap-medientreff.de und http://www.dgap.de |
185280 14.09.2012 |